Want to see AU:ATX full AI Analyst Report?

Amplia Therapeutics (ATX) Price & Analysis

23 Followers

ATX Stock Chart & Stats

AU$0.14

-AU$0.01(-7.14%)

At close: Jul 27 4:00 PM EDT

AU$0.14

-AU$0.01(-7.14%)

Day’s Range― - ―

52-Week RangeAU$0.08 - AU$0.28

Previous CloseN/A

Volume422.49K

Average Volume (3M)1.01M

Market Cap

AU$40.55M

Enterprise ValueAU$93.06M

Total Cash (Recent Filing)AU$27.85M

Total Debt (Recent Filing)AU$341.11K

Price to Earnings (P/E)―

Beta0.56

Next Earnings

Nov 25, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.02

Shares Outstanding513,312,000

10 Day Avg. Volume2,433,521

30 Day Avg. Volume1,012,857

Financial Highlights & Ratios

PEG Ratio0.61

Price to Book (P/B)2.80

Price to Sales (P/S)0.00

P/FCF Ratio-12.59

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

AU$0.42

Price Target Upside200.00% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-0.02

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Equity Cushion And Low LeverageThe substantial equity cushion and generally low leverage provide financial resilience relative to the company’s asset base. This structure may give Amplia more flexibility to fund development activities and absorb operating losses, although ongoing cash consumption remains an important constraint.

Prior Gross Margin PotentialStrong gross profit margins in periods when revenue was generated indicate that the underlying economics of the company’s commercial or partnered activity can be attractive. If revenue is restored, this margin profile could support operating leverage, though current scale is insufficient to cover costs.

Focused Oncology Development PlatformA focused development strategy around FAK biology and a lead oncology candidate can concentrate limited resources behind a defined therapeutic thesis. Combining narmafotinib with standard-of-care treatments also positions the program within established treatment pathways rather than requiring an entirely standalone approach.

Bears Say

Revenue Has Fallen To ZeroThe collapse from prior revenue to zero demonstrates that the company currently lacks recurring commercial income to support its operations. This leaves financial performance dependent on development progress and future funding or licensing outcomes, making near-term business sustainability less predictable.

Worsening Cash BurnIncreasing operating cash burn indicates that the company is consuming capital more rapidly while still lacking positive cash generation. Continued negative operating and free cash flow can reduce the duration of available funding and may constrain the pace or breadth of clinical development over the next several quarters.

Persistent Losses And Negative ReturnsRecurring operating and net losses show that the current business model is not yet covering its cost base, while negative returns indicate the capital base is not producing profitable output. Until development activity translates into revenue or other income, profitability remains structurally unproven.

Amplia Therapeutics News

Amplia advances narmafotinib program as pancreatic cancer trial nears completion

An announcement from Amplia Therapeutics ( ($AU:ATX) ) is now available. Amplia reported continued progress in the clinical...

1d ago

Amplia Therapeutics Secures A$4.78m R&D Tax Rebate to Advance Pancreatic Cancer Trials

Amplia Therapeutics ( ($AU:ATX) ) has shared an update. Amplia Therapeutics has received an A$4.78 million refundable Research...

7d ago

Amplia Therapeutics Advances Narmafotinib Clinical Pipeline in Pancreatic and Ovarian Cancer

Amplia Therapeutics ( ($AU:ATX) ) just unveiled an update. Amplia Therapeutics has reported progress across several clinical trials...

7d ago

Amplia Showcases FAK Inhibitor Progress at CG Drug and Device Conference

Amplia Therapeutics ( ($AU:ATX) ) has provided an announcement. Amplia Therapeutics has released CEO Chris Burns’ presentation delivered...

16d ago

Amplia Showcases FAK Oncology Pipeline at E&P Healthcare Conference

An announcement from Amplia Therapeutics ( ($AU:ATX) ) is now available. Amplia Therapeutics said Chief Executive Officer and...

1M ago

Amplia Wins Strong Shareholder Backing for AGM Resolutions and Capital Flexibility

The latest update is out from Amplia Therapeutics ( ($AU:ATX) ). Amplia Therapeutics said all resolutions at its...

2M ago

Amplia Therapeutics Highlights Strong Pancreatic Cancer Data in AGM CEO Presentation

An update from Amplia Therapeutics ( ($AU:ATX) ) is now available. Amplia Therapeutics has released the CEO and...

2M ago

Amplia Showcases Lead FAK Inhibitor as Pancreatic Cancer Data Strengthen Oncology Push

Amplia Therapeutics ( ($AU:ATX) ) has issued an announcement. Amplia Therapeutics has released a presentation for the Bioshares...

3M ago

Amplia bolsters narmafotinib case with comprehensive pancreatic cancer data

Amplia Therapeutics ( ($AU:ATX) ) has provided an announcement. Amplia Therapeutics has highlighted new preclinical research on its...

3M ago

Amplia advances FAK inhibitor program with new trials, patent gains and board refresh

An update from Amplia Therapeutics ( ($AU:ATX) ) is now available. Amplia reported mature data from its ACCENT...

3M ago

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

7M ago

RADX

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

7M ago

ATX FAQ

What was Amplia Therapeutics Ltd.’s price range in the past 12 months?

Amplia Therapeutics Ltd. lowest share price was AU$0.08 and its highest was AU$0.28 in the past 12 months.

What is Amplia Therapeutics Ltd.’s market cap?

Amplia Therapeutics Ltd.’s market cap is AU$40.55M.

When is Amplia Therapeutics Ltd.’s upcoming earnings report date?

Amplia Therapeutics Ltd.’s upcoming earnings report date is Nov 25, 2026 which is in 27 days.

How were Amplia Therapeutics Ltd.’s earnings last quarter?

Amplia Therapeutics Ltd. released its earnings results on May 29, 2026. The company reported -AU$0.007 earnings per share for the quarter.

Is Amplia Therapeutics Ltd. overvalued?

According to Wall Street analysts Amplia Therapeutics Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Amplia Therapeutics Ltd. pay dividends?

Amplia Therapeutics Ltd. does not currently pay dividends.

What is Amplia Therapeutics Ltd.’s EPS estimate?

Amplia Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Amplia Therapeutics Ltd. have?

Amplia Therapeutics Ltd. has 513,312,000 shares outstanding.

What happened to Amplia Therapeutics Ltd.’s price movement after its last earnings report?

Amplia Therapeutics Ltd. reported an EPS of -AU$0.007 in its last earnings report. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Amplia Therapeutics Ltd.?

Currently, no hedge funds are holding shares in AU:ATX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Amplia Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-18.71%

Trailing 12-Months

Asset Growth

98.58%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Amplia Therapeutics Ltd.

Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.

Amplia Therapeutics (ATX) Earnings & Revenues

Historic Earnings Reports

ATX Stock 12 Month Forecast

Average Price Target

AU$0.42

▲(200.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"AU$0","1":"AU$1","-1":"-AU$1","-0.5":"-AU$0.5","0.5":"AU$0.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$0.42</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$0.42</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.42,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$0.42</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.5,0,0.5,1],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.115,0.13846153846153847,0.16192307692307692,0.18538461538461537,0.20884615384615385,0.23230769230769233,0.25576923076923075,0.2792307692307692,0.3026923076923077,0.3261538461538461,0.3496153846153846,0.3730769230769231,0.3965384615384615,{"y":0.42,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.115,0.13846153846153847,0.16192307692307692,0.18538461538461537,0.20884615384615385,0.23230769230769233,0.25576923076923075,0.2792307692307692,0.3026923076923077,0.3261538461538461,0.3496153846153846,0.3730769230769231,0.3965384615384615,{"y":0.42,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.115,0.13846153846153847,0.16192307692307692,0.18538461538461537,0.20884615384615385,0.23230769230769233,0.25576923076923075,0.2792307692307692,0.3026923076923077,0.3261538461538461,0.3496153846153846,0.3730769230769231,0.3965384615384615,{"y":0.42,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.17,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.14,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.135,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.15,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.125,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.12,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.265,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.15,"date":1777593600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.125,"date":1780272000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.15,"date":1782864000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.13,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.135,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.115,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >